Cell-Surface Glycoconjugates Controlling Human T-Lymphocyte Homing: Implications for Bronchial Asthma and Atopic Dermatitis

2012 ◽  
pp. 167-176 ◽  
Author(s):  
Reiji Kannagi ◽  
Keiichiro Sakuma ◽  
Katsuyuki Ohmori
Keyword(s):  
Atopic Dermatitis ◽  
Cell Surface ◽  
Bronchial Asthma ◽  
T Lymphocyte ◽  
Lymphocyte Homing ◽  
Human T Lymphocyte ◽  
Cell Surface Glycoconjugates

Quantification of gold labeled cell surface antigens by SEM: Current progress and remaining problems

1990 ◽  
Vol 48 (3) ◽  
pp. 34-35
Author(s):  
Etienne de Harven ◽  
Davide Soligo ◽  
Roy McGroarty ◽  
Hilary Christensen ◽  
Richard Leung ◽  
...  
Keyword(s):  
Cell Surface ◽  
Immunogold Labeling ◽  
Target Antigen ◽  
Facs Analysis ◽  
Becton Dickinson ◽  
Cell Surface Antigens ◽  
Human T Lymphocyte ◽  
Backscattered Electron ◽  
Imaging Mode ◽  
Electron Imaging

Taking advantage of the high elemental contrast of particles of colloidal gold observed in the backscattered electron imaging(BEI) mode of the SEM (1,2), the human T lymphocyte was chosen as a model system to study the potential value of immunogold labeling for the quantification of cell surface expressed molecules. The CD3 antigen which is expressed on all human T lymphocytes and is readily identified by the LEU-4 murine monoclonal antibody (Becton Dickinson, Mountain View, CA) followed by a gold conjugated goat anti-mouse Ig polyclonal antibody was chosen as a model target antigen. When quantified by non-EM methods, using radio-iodinated probes or FACS analysis, approximately 30,000 to 50,000 copies of this antigen per cell are enumerated.The following observations were made while attempting to quantify the same molecule by SEM after specific immunogold labeling:Imaging in the SE vs BE mode: The numbers of gold markers counted in the secondary electron (SE) imaging mode are considerably lower than those counted on the same cells in the backscattered electron (BE) imaging mode.

Atopic dermatitis: new horizons of therapy

2019 ◽  
Vol 1 (7) ◽  
pp. 29-32 ◽  
Author(s):  
L. S. Kruglova ◽  
E. M. Gensler
Keyword(s):  
Blood Pressure ◽  
Immune Response ◽  
Allergic Rhinitis ◽  
Atopic Dermatitis ◽  
Targeted Therapy ◽  
Inflammatory Response ◽  
Bronchial Asthma ◽  
New Horizons ◽  
The Past

Over the past decades, the first breakthrough milestone in the treatment of severe forms of atopic dermatitis (AD) has been targeted therapy aimed at inhibiting IL-4 and IL-13. This was made possible thanks to advances in the understanding of the pathogenesis of AD, the driver of which is the Th2-type immune response, which also underlies such manifestations of atopy as bronchial asthma, allergic rhinitis, and polynosis. In the case of the Th2-type immune response, cytokines IL-4 and IL-13 are secreted, which are the main promoters of the inflammatory response in AD. Inhibition of IL-4 and IL-13 leads to the prevention of inflammation and is an effective approach to therapy. The use of therapy aimed at inhibition of cytokines allows you to effectively cope with the manifestations of severe and moderately severe blood pressure.

Sign in / Sign up

Export Citation Format

Share Document